Print

Active Biotech: Interim report January - March 2017

2017-04-27

Laquinimod

  • The clinical trials CONCERTO, ARPEGGIO and LEGATO-HD are progressing according to plan
  • The study results from the pivotal clinical Phase 3 CONCERTO trial in relapsing remitting multiple sclerosis (RRMS) are expected in the first half of 2017
  • The study results from the clinical Phase 2 ARPEGGIO trial, evaluating laquinimod for the treatment of primary progressive multiple sclerosis (PPMS), are expected in the second half of 2017
  • Orphan Drug Designation granted for laquinimod for the treatment of Huntington's disease by the US Food and Drug Administration (FDA)

ANYARA

  • Project proceeding according to plan

Tasquinimod, paquinimod and SILC

  • Out-licensing activities are continuing
  • The European Patent Office has granted a patent application covering tasquinimod for use in the treatment of multiple myeloma
  • Orphan Drug Designation granted for tasquinimod for the treatment of multiple myeloma by the US Food and Drug Administration (FDA)
  • Product patent for SILC substances granted by the European Patent Office

Financial summary

SEK M Jan.-Mar. Full-year
2017 2016 2016
Net sales 4.7 3.9 19.0
Operating loss -14.6 -16.1 -55.1
Loss after tax -15.8 -16.8 -59.6
Loss per share, before and after dilution (SEK) -0.16 -0.19 -0.65
Cash and cash equivalents (at close of period) 62.7 76.5 77.7
  • Operations are progressing according to plan pending the Phase 3 results for laquinimod in the first half of 2017

For further information, please contact:

Tomas Leanderson, President and CEO
Tel: +46 (0) 46 19 20 95



Hans Kolam, CFO
Tel: +46 (0)46 19 20 44

Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46-19 20 00

The report is also available at www.activebiotech.com.


pdfActive Biotech AB Interim report January - March 2017



Back